Discover and read the best of Twitter Threads about #ASCO

Most recents (1)

Looks like Osimertinib, Aztrazenica's 17k a month drug, will present adjuvant data in EGFRm+ NSCLC at #ASCO

Before even reading the paper, let me tell you how to critically appraise it [Thread]
If the trial has a DFS benefit without an OS benefit, that is not good enough

We won't know if we are merely delaying inevitable metastatic recurrence vs. actually curing people

Targeted TKIs don't do well in the adjuvant setting at increasing cure rates
If the trial has an OS benefit, look at the EGFR drugs given to the control arm

It better NOT BE gefitinib.

If you compare adjuvant osi to gefitinib at recurrence you are running a straw man trial.

The same PI who gives Osi frontline, can't accept gefitinib to control arm
Read 5 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!